Appili Therapeutics Inc (APLIF PINK) stock market data APIs
$0.0118
0(0%)
as of July 3, 2025
Try our APIs with
free plan!
Appili Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin which is in Phase III clinical trials for the treatment of cutaneous leishmaniasis; and ATI-1701, which is a live-attenuated vaccine that is in preclinical trials for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Prev. Close
0.0118
Open
0.0118
High
0.0118
Low
0.0118
52 wk Range
0.009-0.0349
Market Cap
1 091 K
Shares Outstanding
121 M
Revenue
100 K
EPS
0.0014
Beta
-0.467
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Appili Therapeutics Inc data using free add-ons & libraries
Get Appili Therapeutics Inc Fundamental Data
Appili Therapeutics Inc Fundamental data includes:
- Net Revenue: 100 K
- EBITDA: -10 071 599
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-26
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Appili Therapeutics Inc News
New
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
Topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease in Phase 3 study ATI-1801 may be eligible for tropical disease priority review vouch...
Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from...
UPDATE – Life Sciences Investor Forum: Company Executives Present Live March 10th
Virtual Investor Conferences Company Executives share vision and answer questions live at VirtualInvestorConferences.com NEW YORK, March 08, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
